Glucagon Action: In-Depth Analysis of Its Application Scope in Peptide Therapy
Abstract: Glucagon action, primarily via cAMP/PKA signaling, underpins its critical role in peptide therapy for severe hypoglycemia and diagnostic applications. Current market trends show a 7.8% CAGR (2024-2030) in peptide therapeutics, driven by glucagon-like analogs. Leading brands (e.g., Eli Lilly’s Glucagon, Xeris’s Gvoke) differ in stability and auto-injector technology. Key advantages include rapid glycemic response; disadvantages involve short half-life and formulation instability. Comparative analysis of product parameters (purity >98%, bioactivity >95%) and regulatory certifications (FDA, EMA) is essential. Selection criteria prioritize cold-chain logistics (2-8°C) and lyophilized formulations for enhanced shelf-life. Industry data indicates glucagon’s expanding scope in metabolic disorders, with factory GMP compliance and batch-to-batch consistency as critical quality benchmarks.